NIH-funded research R01 grant

CCR2 PET imaging in head and neck cancer

Official title: CCR2 PET imaging head and neck squamous cell carcinoma

Funded at Washington University · NIH-11342138 · Data updated 2026-11-12

A new PET imaging approach uses a CCR2-targeted tracer to visualize cancer and immune cells in head and neck squamous cell carcinoma (HNSCC) to help guide treatment.

More Carcinoma research and trials

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionWashington University
NIH-funded
Lab location1 site (Saint Louis, United States)
Project startAugust 5, 2026
Project endJuly 31, 2031
Funding year2026
Award (this year)$637,394
NIH project number1R01CA311526-01
Project IDNIH-11342138 on NIH RePORTER

Who could benefit from this research

Could help

Adults with newly diagnosed head and neck squamous cell carcinoma, particularly those with advanced-stage disease and potential lymph node involvement.

Less likely to help

Patients with tumors not expressing CCR2 or who are unable to undergo PET imaging may derive little or no benefit.

What this research studies

This project aims to use a CCR2-targeted PET radiotracer, 64Cu-DOTA-ECL1i, to image tumors and tumor-associated macrophages in patients with newly diagnosed head and neck squamous cell carcinoma. By combining PET/CT imaging with biomarker information, doctors may better predict prognosis and tailor therapies for each patient. The study builds on prior findings showing CCR2 expression is linked with worse outcomes and that the tracer can visualize CCR2+ cells in tumors. Enrollment would involve imaging participants and correlating imaging findings with clinical outcomes and pathology. The goal is to create an imaging biomarker that helps select the most effective treatment strategy for HNSCC patients.

Why it matters

Potential benefit: If successful, patients could receive more personalized treatment plans based on tumor CCR2 activity and immune cell presence as seen on PET imaging.

How similar studies have gone: Preliminary imaging in some HNSCC patients showed tracer uptake in tumors and lymph nodes, supporting potential clinical utility, though broader validation is needed.

Where this research is happening

  • Washington University
    Saint Louis, United States
    Active

Researchers

  • Principal investigator: Dehdashti, Farrokh — Washington University
  • Study coordinator: Dehdashti, Farrokh

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.